Skip to main content
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. — Investor Relations & Filings

Ticker · JANX ISIN · US47103J1051 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2026-04-28 Board/Management Inform…
Country US United States of America
Listing US JANX

About Janux Therapeutics, Inc.

https://www.januxrx.com/

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. The company utilizes its proprietary Tumor Activated T Cell Engager (TRACTr) platform to engineer therapeutics designed for conditional activation within the tumor microenvironment. This technology aims to create highly specific treatments that direct the immune system to attack cancer cells while minimizing systemic toxicity associated with conventional T cell engagers. Janux is advancing a pipeline of these precision-engineered therapies to address solid tumors.

Recent filings

Filing Released Lang Actions
8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated April 28, 2026, by Janux Therapeutics, Inc. The key content is about the departure and reappointment of a director to rebalance the classes of directors on the Board. This is a clear announcement of changes in the company's board of directors. There is no financial data or report attached, nor is it a report publication announcement. The document fits the category of Board/Management Information (MANG) as it concerns board membership changes.
2026-04-28 English
10-K - JANUX THERAPEUTICS, INC. (0001817713) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - JANUX THERAPEUTICS, INC. (0001817713) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, specifically reporting "Results of Operations and Financial Condition" with an attached press release announcing financial results for the year ended December 31, 2025. The text states that the press release is attached as Exhibit 99.1 and that the information is being furnished and not filed, indicating this is an earnings release type announcement rather than a full annual report or detailed financial statement. The document length is 3608 characters, which is relatively short and consistent with an earnings release announcement. Therefore, this document is best classified as an Earnings Release (ER).
2026-02-26 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-06 English
4 Filing
Director's Dealing
2026-02-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.